{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:29:20Z","timestamp":1786613360906,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Health~Holland, reference number AMR-23645"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41434-026-00601-9","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:49:37Z","timestamp":1773146977000},"page":"398-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AAV-mediated gene replacement therapy for LRAT-associated retinitis pigmentosa: a proof-of-concept study in a patient-based rat model"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8292-0016","authenticated-orcid":false,"given":"A. M.","family":"El-Kalaani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-0067","authenticated-orcid":false,"given":"J. B.","family":"Ten Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J. F.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-3970","authenticated-orcid":false,"given":"C.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"601_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101324","volume":"107","author":"JS Karuntu","year":"2024","unstructured":"Karuntu JS, Almushattat H, Nguyen XTA, Plomp AS, Wanders RJA, Hoyng CB, et al. Syndromic retinitis pigmentosa. Prog Retin Eye Res. 2024;107:101324.","journal-title":"Prog Retin Eye Res"},{"key":"601_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","volume":"66","author":"SK Verbakel","year":"2018","unstructured":"Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018;66:157\u201386.","journal-title":"Prog Retin Eye Res"},{"key":"601_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02798-z","volume":"18","author":"V Murro","year":"2023","unstructured":"Murro V, Banfi S, Testa F, Iarossi G, Falsini B, Sodi A, et al. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet J Rare Dis. 2023;18:223.","journal-title":"Orphanet J Rare Dis"},{"key":"601_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4103\/1673-5374.350192","volume":"18","author":"G Kaur","year":"2023","unstructured":"Kaur G, Singh NK. Inflammation and retinal degenerative diseases. Neural Regen Res. 2023;18:513\u20138.","journal-title":"Neural Regen Res"},{"key":"601_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1085\/jgp.200609557","volume":"128","author":"P Ala-Laurila","year":"2006","unstructured":"Ala-Laurila P, Kolesnikov AV, Crouch RK, Tsina E, Shukolyukov SA, Govardovskii VI, et al. Visual cycle: dependence of retinol production and removal on photoproduct decay and cell morphology. J Gen Physiol. 2006;128:153\u201369.","journal-title":"J Gen Physiol"},{"key":"601_CR6","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.TR120000850","volume":"62","author":"EH Choi","year":"2021","unstructured":"Choi EH, Daruwalla A, Suh S, Leinonen H, Palczewski K. Retinoids in the visual cycle: role of the retinal G protein-coupled receptor. J Lipid Res. 2021;62:100040.","journal-title":"J Lipid Res"},{"key":"601_CR7","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1242\/jcs.175687","volume":"128","author":"RS Molday","year":"2015","unstructured":"Molday RS, Moritz OL. Photoreceptors at a glance. J Cell Sci. 2015;128:4039\u201345.","journal-title":"J Cell Sci"},{"key":"601_CR8","doi-asserted-by":"publisher","first-page":"13016","DOI":"10.1074\/jbc.AW118.003228","volume":"293","author":"A Tsin","year":"2018","unstructured":"Tsin A, Betts-Obregon B, Grigsby J. Visual cycle proteins: structure, function, and roles in human retinal disease. J Biol Chem. 2018;293:13016\u201321.","journal-title":"J Biol Chem"},{"key":"601_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbalip.2011.03.005","volume":"1821","author":"PD Kiser","year":"2012","unstructured":"Kiser PD, Golczak M, Maeda A, Palczewski K. Key enzymes of the retinoid (visual) cycle in vertebrate retina. Biochim Biophys Acta. 2012;1821:137\u201351.","journal-title":"Biochim Biophys Acta"},{"key":"601_CR10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.ajhg.2025.08.017","volume":"112","author":"SP Daiger","year":"2025","unstructured":"Daiger SP, Sullivan LS. RetNet: summaries of genes and loci causing retinal diseases. Am J Hum Genet 2025;112:2253\u201365.","journal-title":"Am J Hum Genet"},{"key":"601_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cge.12203","volume":"84","author":"SP Daiger","year":"2013","unstructured":"Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa: genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84:132\u201341.","journal-title":"Clin Genet"},{"key":"601_CR12","first-page":"31","volume":"42","author":"A Ruiz","year":"2001","unstructured":"Ruiz A, Kuehn MH, Andorf JL, Stone E, Hageman GS, Bok D. Genomic organization and mutation analysis of the gene encoding lecithin retinol acyltransferase in human retinal pigment epithelium. Investig Ophthalmol Vis Sci. 2001;42:31\u20137.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR13","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1074\/jbc.274.6.3834","volume":"274","author":"A Ruiz","year":"1999","unstructured":"Ruiz A, Winston A, Lim YH, Gilbert BA, Rando RR, Bok D. Molecular and biochemical characterization of lecithin retinol acyltransferase. J Biol Chem. 1999;274:3834\u201341.","journal-title":"J Biol Chem"},{"key":"601_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.preteyeres.2008.05.003","volume":"27","author":"AI Den Hollander","year":"2008","unstructured":"Den Hollander AI, Roepman R, Koenekoop RK, Cremers FPM. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res. 2008;27:391\u2013419.","journal-title":"Prog Retin Eye Res"},{"key":"601_CR15","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1167\/iovs.07-0610","volume":"48","author":"AI Den Hollander","year":"2007","unstructured":"Den Hollander AI, Lopez I, Yzer S, Zonneveld MN, Janssen IM, Strom TM, et al. Identification of novel mutations in patients with Leber congenital amaurosis and juvenile RP by genome-wide homozygosity mapping with SNP microarrays. Investig Ophthalmol Vis Sci. 2007;48:5690\u20138.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/tvst.8.4.24","volume":"8","author":"M Talib","year":"2019","unstructured":"Talib M, van Schooneveld MJ, van Duuren RJG, Van Cauwenbergh C, Ten Brink JB, De Baere E, et al. Long-term follow-up of retinal degenerations associated with LRAT mutations and their comparability to phenotypes associated with RPE65 mutations. Transl Vis Sci Technol. 2019;8:24.","journal-title":"Transl Vis Sci Technol"},{"key":"601_CR17","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1167\/iovs.12-9548","volume":"53","author":"A Dev Borman","year":"2012","unstructured":"Dev Borman A, Ocaka LA, Mackay DS, Ripamonti C, Henderson RH, Moradi P, et al. Early-onset retinal dystrophy due to mutations in LRAT: molecular analysis and detailed phenotypic study. Investig Ophthalmol Vis Sci. 2012;53:3927.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/88828","volume":"28","author":"DA Thompson","year":"2001","unstructured":"Thompson DA, Li Y, McHenry CL, Carlson TJ, Ding X, Sieving PA, et al. Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy. Nat Genet. 2001;28:123\u20134.","journal-title":"Nat Genet"},{"key":"601_CR19","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1371\/journal.pmed.0020333","volume":"2","author":"ML Batten","year":"2005","unstructured":"Batten ML, Imanishi Y, Tu DC, Doan T, Zhu L, Pang J, et al. Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of Leber congenital amaurosis. PLoS Med. 2005;2:e333.","journal-title":"PLoS Med"},{"key":"601_CR20","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.3390\/ijms22137234","volume":"22","author":"C Koster","year":"2021","unstructured":"Koster C, van den Hurk KT, Lewallen CF, Talib M, Ten Brink JB, Boon CJF, et al. The Lrat-\/- rat: CRISPR\/Cas9 construction and phenotyping of a new animal model for retinitis pigmentosa. Int J Mol Sci. 2021;22:7234.","journal-title":"Int J Mol Sci"},{"key":"601_CR21","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.ophtha.2012.02.037","volume":"119","author":"KW Littink","year":"2012","unstructured":"Littink KW, Van Genderen MM, Van Schooneveld MJ, Visser L, Riemslag FCC, Keunen JEE, et al. A homozygous frameshift mutation in LRAT causes retinitis punctata albescens. Ophthalmology. 2012;119:1899\u2013906.","journal-title":"Ophthalmology"},{"key":"601_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53.","journal-title":"Signal Transduct Target Ther"},{"key":"601_CR23","doi-asserted-by":"crossref","unstructured":"Ronzitti G, Gross DA, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2020;11. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.00670.","DOI":"10.3389\/fimmu.2020.00670"},{"key":"601_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/OPTH.S364200","volume":"16","author":"HH Ghoraba","year":"2022","unstructured":"Ghoraba HH, Akhavanrezayat A, Karaca I, Yavari N, Lajevardi S, Hwang J, et al. Ocular Gene therapy: a literature review with special focus on immune and inflammatory responses. Clin Ophthalmol Auckl NZ. 2022;16:1753\u201371.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"601_CR25","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","volume":"10","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, Kobinger G, Anand V, Hildinger M, O\u2019Connor E, Maguire AM, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet. 2001;10:3075\u201381.","journal-title":"Hum Mol Genet"},{"key":"601_CR26","doi-asserted-by":"publisher","first-page":"11372","DOI":"10.1128\/JVI.01327-07","volume":"81","author":"M Allocca","year":"2007","unstructured":"Allocca M, Mussolino C, Garcia-Hoyos M, Sanges D, Iodice C, Petrillo M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol. 2007;81:11372\u201380.","journal-title":"J Virol"},{"key":"601_CR27","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1089\/hum.2020.043","volume":"31","author":"IC Han","year":"2020","unstructured":"Han IC, Cheng JL, Burnight ER, Ralston CL, Fick JL, Thomsen GJ, et al. Retinal tropism and transduction of adeno-associated virus varies by serotype and route of delivery (intravitreal, subretinal, or suprachoroidal) in rats. Hum Gene Ther. 2020;31:1288\u201399.","journal-title":"Hum Gene Ther"},{"key":"601_CR28","doi-asserted-by":"crossref","unstructured":"Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, et al. In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5. Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.3005708.","DOI":"10.1126\/scitranslmed.3005708"},{"key":"601_CR29","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","volume":"23","author":"AW Taylor","year":"2009","unstructured":"Taylor AW. Ocular immune privilege. Eye. 2009;23:1885\u20139.","journal-title":"Eye"},{"key":"601_CR30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","volume":"128","author":"AM Maguire","year":"2021","unstructured":"Maguire AM, Russell S, Chung DC, Yu ZF, Tillman A, Drack AV, et al. Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years. Ophthalmology. 2021;128:1460\u20138.","journal-title":"Ophthalmology"},{"key":"601_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126:1273\u201385.","journal-title":"Ophthalmology"},{"key":"601_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet Lond Engl. 2017;390:849\u201360.","journal-title":"Lancet Lond Engl"},{"key":"601_CR33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","volume":"107","author":"FF Reichel","year":"2023","unstructured":"Reichel FF, Seitz I, Wozar F, Dimopoulos S, Jung R, Kempf M, et al. Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. Br J Ophthalmol. 2023;107:1331\u20135.","journal-title":"Br J Ophthalmol"},{"key":"601_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","volume":"6","author":"WS Gange","year":"2022","unstructured":"Gange WS, Sisk RA, Besirli CG, Lee TC, Havunjian M, Schwartz H, et al. Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis. Ophthalmol Retina. 2022;6:58\u201364.","journal-title":"Ophthalmol Retina"},{"key":"601_CR35","unstructured":"National Centre for the Replacement, Refinement & Reduction of Animals in Research. Experimental Design Assistant. Available from: https:\/\/eda.nc3rs.org.uk\/experimental-design-group."},{"key":"601_CR36","doi-asserted-by":"publisher","first-page":"655\u20138","DOI":"10.1101\/pdb.prot073411","volume":"2014","author":"RD Cardiff","year":"2014","unstructured":"Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014;2014:655\u20138.","journal-title":"Cold Spring Harb Protoc"},{"key":"601_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"601_CR38","doi-asserted-by":"publisher","unstructured":"Burke J, Engelmann J, Gibbon S, Hamid C, Moukaddem D, Pugh D, et al. OCTolyzer: fully automatic toolkit for segmentation and feature extraction in optical coherence tomography and scanning laser ophthalmoscopy data. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2407.14128 2024.","DOI":"10.48550\/arXiv.2407.14128"},{"key":"601_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"601_CR40","unstructured":"Core R. Team. R: A language and environment for statistical computing. R Core Team. 2021."},{"key":"601_CR41","unstructured":"signal developers. signal: signal processing. 2014. Available from: http:\/\/r-forge.r-project.org\/projects\/signal\/."},{"key":"601_CR42","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686.","journal-title":"J Open Source Softw"},{"key":"601_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.survophthal.2024.05.004","volume":"69","author":"D L\u2019Abbate","year":"2024","unstructured":"L\u2019Abbate D, Prescott K, Geraghty B, Kearns VR, Steel DHW. Biomechanical considerations for optimising subretinal injections. Surv Ophthalmol. 2024;69:722\u201332.","journal-title":"Surv Ophthalmol"},{"key":"601_CR44","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/0042-6989(93)90121-C","volume":"33","author":"B Hermes","year":"1993","unstructured":"Hermes B, Reuss S, Vollrath L. Strain differences in the ratio of synaptic body types in photoreceptors of the rat retina. Vision Res. 1993;33:2427\u201330.","journal-title":"Vision Res"},{"key":"601_CR45","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1242\/jeb.204.14.2439","volume":"204","author":"GH Jacobs","year":"2001","unstructured":"Jacobs GH, Fenwick JA, Williams GA. Cone-based vision of rats for ultraviolet and visible lights. J Exp Biol. 2001;204:2439\u201346.","journal-title":"J Exp Biol"},{"key":"601_CR46","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1167\/iovs.05-0533","volume":"46","author":"B Rohrer","year":"2005","unstructured":"Rohrer B, Lohr HR, Humphries P, Redmond TM, Seeliger MW, Crouch RK. Cone opsin mislocalization in Rpe65\u2212\/\u2212 mice: a defect that can be corrected by 11-cis retinal. Investig Ophthalmol Vis Sci. 2005;46:3876.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0014-2999(03)01274-3","volume":"463","author":"M Bourin","year":"2003","unstructured":"Bourin M, Hasco\u00ebt M. The mouse light\/dark box test. Eur J Pharmacol. 2003;463:55\u201365.","journal-title":"Eur J Pharmacol"},{"key":"601_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/humc.2019.030","volume":"30","author":"T He","year":"2019","unstructured":"He T, Itano MS, Earley LF, Hall NE, Riddick N, Samulski RJ, et al. The influence of murine genetic background in adeno-associated virus transduction of the mouse brain. Hum Genet Ther Clin Dev. 2019;30:169\u201381.","journal-title":"Hum Genet Ther Clin Dev"},{"key":"601_CR49","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/bit.26031","volume":"113","author":"H Khabou","year":"2016","unstructured":"Khabou H, Desrosiers M, Winckler C, Fouquet S, Auregan G, Bemelmans A, et al. Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol Bioeng. 2016;113:2712\u201324.","journal-title":"Biotechnol Bioeng"},{"key":"601_CR50","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.3390\/ijms23147738","volume":"23","author":"L Carroll","year":"2022","unstructured":"Carroll L, Uehara H, Zhang X, Ambati B. Tropism of the novel AAVBR1 capsid following subretinal delivery. Int J Mol Sci. 2022;23:7738.","journal-title":"Int J Mol Sci"},{"key":"601_CR51","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/hum.2017.154","volume":"29","author":"LS Carvalho","year":"2018","unstructured":"Carvalho LS, Xiao R, Wassmer SJ, Langsdorf A, Zinn E, Pacouret S, et al. Synthetic adeno-associated viral vector efficiently targets mouse and nonhuman primate retina in vivo. Hum Gene Ther. 2018;29:771\u201384.","journal-title":"Hum Gene Ther"},{"key":"601_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.omtn.2022.12.007","volume":"31","author":"Y Hsu","year":"2023","unstructured":"Hsu Y, Bhattarai S, Thompson JM, Mahoney A, Thomas J, Mayer SK, et al. Subretinal gene therapy delays vision loss in a Bardet-Biedl syndrome type 10 mouse model. Mol Ther Nucleic Acids. 2023;31:164\u201381.","journal-title":"Mol Ther Nucleic Acids"},{"key":"601_CR53","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/hum.2016.085","volume":"27","author":"SE Boye","year":"2016","unstructured":"Boye SE, Alexander JJ, Witherspoon CD, Boye SL, Peterson JJ, Clark ME, et al. Highly efficient delivery of adeno-associated viral vectors to the primate retina. Hum Gene Ther. 2016;27:580\u201397.","journal-title":"Hum Gene Ther"},{"key":"601_CR54","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1167\/iovs.07-1622","volume":"49","author":"Jjing Pang","year":"2008","unstructured":"Pang Jjing, Boye SL, Kumar A, Dinculescu A, Deng W, Li J, et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDE\u03b2 mutation. Investig Ophthalmol Vis Sci. 2008;49:4278.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR55","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.visres.2006.11.020","volume":"47","author":"B Chang","year":"2007","unstructured":"Chang B, Hawes NL, Pardue MT, German AM, Hurd RE, Davisson MT, et al. Two mouse retinal degenerations caused by missense mutations in the \u03b2-subunit of rod cGMP phosphodiesterase gene. Vision Res. 2007;47:624\u201333.","journal-title":"Vision Res"},{"key":"601_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1153934","volume":"16","author":"Y Bhatt","year":"2023","unstructured":"Bhatt Y, Hunt DM, Carvalho LS. The origins of the full-field flash electroretinogram b-wave. Front Mol Neurosci. 2023;16:1153934.","journal-title":"Front Mol Neurosci"},{"key":"601_CR57","first-page":"3622","volume":"41","author":"D Lau","year":"2000","unstructured":"Lau D, McGee LH, Zhou S, Rendahl KG, Manning WC, Escobedo JA, et al. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Investig Ophthalmol Vis Sci. 2000;41:3622\u201333.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.","journal-title":"Front Immunol"},{"key":"601_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915","volume":"83","author":"K Bucher","year":"2021","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD. Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 Implications for treatment success and safety. Prog Retin Eye Res. 2021;83:100915.","journal-title":"Prog Retin Eye Res"},{"key":"601_CR60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/tvst.12.11.24","volume":"12","author":"M Sobh","year":"2023","unstructured":"Sobh M, Lagali PS, Ghiasi M, Montroy J, Dollin M, Hurley B, et al. Safety and Efficacy of adeno-associated viral gene therapy in patients with retinal degeneration: a systematic review and meta-analysis. Transl Vis Sci Technol. 2023;12:24.","journal-title":"Transl Vis Sci Technol"},{"key":"601_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41587-020-00756-9","volume":"39","author":"CP Venditti","year":"2021","unstructured":"Venditti CP. Safety questions for AAV gene therapy. Nat Biotechnol. 2021;39:24\u20136.","journal-title":"Nat Biotechnol"},{"key":"601_CR62","doi-asserted-by":"crossref","unstructured":"Suoranta T, Laham-Karam N, Yl\u00e4-Herttuala S. Strategies to improve the safety profile of AAV vectors. Front Mol Med. 2022;2. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2022.1054069.","DOI":"10.3389\/fmmed.2022.1054069"},{"key":"601_CR63","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/pnas.1821000116","volume":"116","author":"W Xiong","year":"2019","unstructured":"Xiong W, Wu DM, Xue Y, Wang SK, Chung MJ, Ji X, et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA. 2019;116:5785\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"601_CR64","first-page":"52247","volume":"95","author":"PD Westenskow","year":"2015","unstructured":"Westenskow PD, Kurihara T, Bravo S, Feitelberg D, Sedillo ZA, Aguilar E, et al. Performing subretinal injections in rodents to deliver retinal pigment epithelium cells in suspension. J Vis Exp. 2015;95:52247.","journal-title":"J Vis Exp."},{"key":"601_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1304819","volume":"11","author":"S Hassan","year":"2024","unstructured":"Hassan S, Hsu Y, Thompson JM, Kalmanek E, VandeLune JA, Stanley S, et al. The dose-response relationship of subretinal gene therapy with rAAV2tYF-CB-hRS1 in a mouse model of X-linked retinoschisis. Front Med. 2024;11:1304819.","journal-title":"Front Med"},{"key":"601_CR66","doi-asserted-by":"publisher","first-page":"e0136523","DOI":"10.1371\/journal.pone.0136523","volume":"10","author":"Y Qi","year":"2015","unstructured":"Qi Y, Dai X, Zhang H, He Y, Zhang Y, Han J, et al. Trans-corneal subretinal injection in mice and its effect on the function and morphology of the retina. PloS One. 2015;10:e0136523.","journal-title":"PloS One"},{"key":"601_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2023.1148795","volume":"3","author":"S Koponen","year":"2023","unstructured":"Koponen S, Kokki E, Tamminen T, Yl\u00e4-Herttuala S. AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery. Front Drug Deliv. 2023;3:1148795.","journal-title":"Front Drug Deliv"},{"key":"601_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02720-4","volume":"22","author":"K Yang","year":"2022","unstructured":"Yang K, Jin X, Wang Z, Fang Y, Li Z, Yang Z, et al. Robot-assisted subretinal injection system: development and preliminary verification. BMC Ophthalmol. 2022;22:484.","journal-title":"BMC Ophthalmol"},{"key":"601_CR69","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11701-024-01991-x","volume":"18","author":"PM \u0141ajczak","year":"2024","unstructured":"\u0141ajczak PM, Nawrat Z. Sharper vision, steady hands: can robots improve subretinal drug delivery? Systematic review. J Robot Surg. 2024;18:235.","journal-title":"J Robot Surg"},{"key":"601_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","volume":"16","author":"G Yiu","year":"2020","unstructured":"Yiu G, Chung SH, Mollhoff IN, Nguyen UT, Thomasy SM, Yoo J, et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther Methods Clin Dev. 2020;16:179\u201391.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"601_CR71","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1167\/iovs.17-22494","volume":"59","author":"FF Reichel","year":"2018","unstructured":"Reichel FF, Peters T, Wilhelm B, Biel M, Ueffing M, Wissinger B, et al. Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients. Investig Ophthalmol Vis Sci. 2018;59:1910.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR72","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1167\/iovs.17-22473","volume":"58","author":"IP Seitz","year":"2017","unstructured":"Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Investig Ophthalmol Vis Sci. 2017;58:5792.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"601_CR73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/bjo-2024-326221","volume":"109","author":"A Daruich","year":"2025","unstructured":"Daruich A, Rateaux M, Batt\u00e9 E, De Vergnes N, Valleix S, Robert MP, et al. 12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy. Br J Ophthalmol. 2025;109:281\u20135.","journal-title":"Br J Ophthalmol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00601-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00601-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00601-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:02:11Z","timestamp":1786611731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00601-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00601-9","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We conducted all animal experiments in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and they were approved by the Netherlands\u2019 national committee and the animal welfare body of the Amsterdam UMC (license number AVD11400202011085, protocol number SP2400053).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}